Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus.

Purpose: Oncolytic poxvirus has shown promise in treating various solid tumors, such as liver cancer, and administration of oncolytic poxvirus via the hepatic artery may provide more survival benefits than other routes of administration. However, there is a lack of safety information to guide the application of hepatic arterial infusion (HAI) of oncolytic poxvirus in human studies. To investigate the acute and chronic toxicity of HAI administration of oncolytic poxvirus in animals and provide safety information for future human studies.

Methods: VV, a vaccinia poxvirus with inactivated gene, was administered via HAI to rabbits with normal liver function under angiography (1×10 or 1×10 pfu), and rats with N-nitrosomorpholine-induced precancerous liver cirrhosis under open surgery (1×10 pfu). Body weights and survival were monitored and blood samples were collected for hematological and biochemical tests. Distribution of A56 (a specific marker for poxvirus infection) in rabbit organs was evaluated using immunofluorescence assays.

Results: HAI of high doses of VV did not cause any acute or chronic changes in body weight, survival or in biochemical, hematological tests in the 2 animal models, and none of the changes showed dose dependency (in rabbit study), or were influenced by liver cirrhosis (in rat study). A56 was not detected in any of the major rabbit organs.

Conclusion: HAI may provide a safe alternative route of oncolytic poxvirus administration for human studies.